Roundup (Glyphosate) Lawsuit Update (August 2026)

Roundup Is Not Over. But the Window Is Closing Fast.

Roundup mass tort marketing remains economically viable for plaintiff firms in 2026, but the claimant pool is narrowing and acquisition costs are rising as the litigation approaches resolution. Bayer has paid over $10 billion in settlements, yet tens of thousands of claims remain unresolved, sustaining real demand for aggressive intake operations. Firms that understand the current case economics, cost per signed case, projected settlement value, and intake conversion rates, can still build a profitable docket. Those that treat this like 2019 cannot.

This post breaks down the litigation clock, the remaining claimant pool, realistic acquisition costs, and how to run intake tightly enough that every signed case is worth keeping. No fluff. Just the business math your firm needs to make a clear-eyed decision.

The Litigation Landscape: What the $7.3B Proposed Settlement Means for Firms

Here is where things stand as of the most current intelligence available. Bayer faces more than 165,000 active claims in MDL 2741, pending before Judge Vince Chhabria in the Northern District of California. Bayer has already deployed the first $10.9 billion settlement program, which resolved roughly 100,000 claims and reserved $4.5 billion for future filings. Now there is a proposed $7.3 billion class settlement on the table designed to resolve all remaining and future Roundup claims permanently.

That proposed class settlement is the single biggest variable in your 2025 and 2026 case acquisition math. If the court approves it, the tort closes. Not slows down. Closes. Any inventory your firm has not finalized by that point is subject to whatever the settlement terms dictate, and new cases filed after approval may receive far less favorable treatment or be excluded entirely depending on how the agreement is structured.

State court trials are continuing in the interim. The bellwether history is strong for plaintiffs. The Dewayne Johnson verdict in 2018 produced an initial $289 million award (reduced to $78 million on appeal), and the Hardeman federal bellwether produced an $80 million verdict upheld by the Ninth Circuit in 2021. SCOTUS denied cert in 2022 on Bayer's federal preemption argument, which means that defense is off the table. The liability picture is about as proven as it gets in mass tort litigation.

The strategic implication for plaintiff firms is this: the settlement point system and the extraordinary circumstances fund are where you need to focus your screening energy, because not all cases pay the same, and the difference between a base-level case and a high-value case in this program is significant enough to change your entire ROI calculation on acquisition spend.

The Settlement Point System and the Extraordinary Circumstances Fund

The Roundup settlement framework uses a point-based valuation system that assigns case value based on several factors: diagnosis type, severity and stage of non-Hodgkin lymphoma, duration and level of Roundup exposure, age at diagnosis, and the presence of other risk factors that could reduce the award. A case with a heavy-use agricultural worker who received an NHL diagnosis at a younger age and has strong medical documentation scores significantly more points than a residential user with limited exposure history and a later-stage diagnosis that could be contested on causation.

Within the settlement structure there is also a mechanism commonly referred to as the extraordinary circumstances fund. This fund is designed to compensate claimants whose cases present unusually severe facts, either extraordinary disease burden, exceptional exposure evidence, or other aggravating factors that distinguish the case from the general pool. These cases can receive substantially higher awards than the standard point-based calculation would produce. From a firm-side screening standpoint, identifying extraordinary circumstances cases early in intake is worth real money. Your intake team should be trained to flag these specifically, not treat every NHL diagnosis as equivalent.

For attorneys doing Roundup mass tort marketing right now, the practical implication is to market to the highest-exposure populations first and screen aggressively for case quality on the back end. Signing weak cases that score low in the point system or fail extraordinary circumstances thresholds will drag your per-case revenue down fast.

The Claimant Pool: Is There Still Volume to Capture?

The honest answer is yes, but less than two years ago, and the remaining pool is more concentrated. The addressable universe of people with documented Roundup exposure and an NHL diagnosis is not exhausted. Agricultural states hold the highest concentrations: California, Iowa, Nebraska, and Kansas are the primary plaintiff pools. Farming communities, commercial landscapers, golf course workers, and heavy residential users in rural areas are where legitimate claimants still exist who have not yet engaged an attorney.

That said, saturation in the general consumer advertising space is real. National TV and digital campaigns ran hard from 2019 through 2022, and a significant portion of the most accessible claimants were signed during that period. The remaining pool skews toward harder-to-reach populations: older rural residents, agricultural workers who are not heavy digital consumers, and people who received an NHL diagnosis years ago but never connected it to their Roundup use.

This changes your channel strategy. Broadcast and general Facebook targeting alone will not produce the volume or quality it once did at reasonable cost. Geographic and demographic precision matters more now than at any prior point in this campaign's history.

Roundup Mass tort Marketing Economics: What Cases Actually Cost to Acquire

Realistic numbers for Roundup mass tort marketing in 2025 vary by channel and by how tightly your intake funnel is built, but here is a working range based on current market conditions.

Cost per lead on paid social, running targeted campaigns toward agricultural demographics and relevant geographic concentrations, is running roughly $150 to $350 per lead depending on creative, targeting specificity, and competition in the auction. Cost per signed case after intake qualification is typically in the $1,500 to $3,500 range when campaigns are run cleanly. Some firms running looser intake processes are seeing signed-case costs climb above $4,000 because they are signing unqualified cases that fall out downstream.

Google search still produces intent-driven leads but cost per click on the core Roundup terms is expensive given the competition from national advertisers and co-counsel aggregators. The better search play for most firms is long-tail geographic and symptom-adjacent keywords that match the specific qualifying criteria: farmers with NHL, agricultural workers lymphoma, and similar constructions that surface higher-intent, lower-competition traffic.

Creative that converts in this campaign is direct and exposure-focused. It does not need to be sensationalized. The IARC Group 2A classification, the documented verdict history, and the straightforward exposure-to-diagnosis story are compelling enough. The creative angles that produce the best lead quality highlight specific occupations and use patterns rather than generic pesticide messaging.

On Facebook and Meta platforms specifically, the custom audience and lookalike strategies built from existing claimant data outperform cold interest-based targeting by a meaningful margin. Firms that have run this tort before have a real advantage here if they have retained their audience data.

Intake and Qualification: What Makes a Roundup Case Worth Keeping

Intake on Roundup cases needs to move fast right now given the settlement approval timeline, but fast intake that signs weak cases creates more problems than it solves. Your qualification checklist should cover four things with no exceptions.

• Confirmed NHL diagnosis with supporting medical records, not just a self-reported cancer history.
• Documented or clearly articulable Roundup exposure, with enough frequency and duration to support causation under the IARC framework. Occasional residential use is a harder case than regular occupational use. Your screeners need to know the difference.
• Diagnosis timing and statute of limitations review by jurisdiction. This tort has been running long enough that some potential claimants are outside the window in their state.
• Absence of disqualifying alternative causation factors that would score the case low in the point system or expose it to a causation challenge at allocation.

The firms generating the best per-case returns on Roundup right now are also screening specifically for extraordinary circumstances potential during initial intake, not leaving that identification to later review. A trained intake specialist who knows to ask the right follow-up questions about disease severity, treatment history, and exposure duration can flag a case that belongs in the extraordinary circumstances tier during the first call. That is recoverable value that sloppy intake leaves on the table.

Retainer flow should be electronic and fast. Claimants in the agricultural demographic are not always comfortable with prolonged document exchanges. A streamlined e-sign process with clear follow-up for records collection is the standard that works in this population.

How MTAA Runs Roundup Campaigns

At Mass Tort Ad Agency we have managed Roundup campaigns across multiple phases of this litigation for plaintiff firms nationwide, from the early post-Johnson verdict surge through the current settlement-pending environment. Our model is transparent cost-plus: your actual ad spend plus a 15% management fee, no markups buried in the media buy, no games with lead pricing. Across more than $250 million in managed ad spend for 600-plus plaintiff firms on more than 100 torts, we have built the audience data, the creative frameworks, and the channel-specific targeting that this particular tort requires right now.

Given the settlement timeline, we are counseling firms that want to run Roundup acquisition to move quickly, set tight qualification criteria from day one, and build their intake flow for speed without sacrificing the screening quality that determines case value under the point system. Firms that want to explore whether a Roundup campaign makes sense for their current docket and budget can reach out directly through our site.

The Bottom Line on Roundup Mass Tort Marketing in 2025 and 2026

Roundup mass tort marketing is not a campaign to run casually at this stage. The liability is proven, the science is solid, and the settlement structures produce real per-case value for well-documented claims. But the window is genuinely closing, and the difference between a profitable campaign and a money-losing one comes down entirely to acquisition cost discipline and intake quality. Firms that screen for the settlement point system and identify extraordinary circumstances cases early will outperform firms that treat this like a volume play. If your firm has capacity for Roundup cases and a tightly run intake process, there is still a defensible business case for new acquisition investment. If you are hoping to ride general awareness advertising to easy volume, that ship has sailed.